The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|8|E1-E6

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.8, 2015-04, pp. : E1-E6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 91, Iss. 1, 2016-07 ,pp. : 26-34

Karger

Access to resources Recommend Favorite

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4325-4332

John Wiley & Sons Inc

Access to resources Recommend Favorite

Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer

By  

CANCER, Vol. 120, Iss. 15, 2014-08 ,pp. : 2289-2298

John Wiley & Sons Inc

Access to resources Recommend Favorite

Uterine metastasis of lung adenocarcinoma under molecular target therapy with epidermal growth factor receptor tyrosine kinase inhibitors: A case report and review of the literature

By  

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (ELECTRONIC), Vol. 44, Iss. 2, 2018-02 ,pp. : 352-358

John Wiley & Sons Inc

Access to resources Recommend Favorite

Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: A Review of Recent Clinical Trials

By  

Reviews on Recent Clinical Trials, Vol. 2, Iss. 2, 2007-05 ,pp. : 117-120

Bentham Science Publishers

Access to resources Recommend Favorite